Trial Profile
An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Methotrexate (Primary) ; TAS-5315 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 22 May 2023 Primary endpoint has not been met (Proportion of participants achieving American College of Rheumatology 20% (ACR20) response), as per Results published in the Annals of the Rheumatic Diseases
- 22 May 2023 Results published in the Annals of the Rheumatic Diseases
- 14 Aug 2020 Status changed from active, no longer recruiting to completed.